Related Experiment Video

Updated: Apr 30, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.2K

Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review

Patricia Rojas Sánchez1, Africa Holguín2

  • 1HIV-1 Molecular Epidemiology Laboratory, Microbiology Department, Hospital Ramón y Cajal-IRYCIS and CIBERESP, Madrid, Spain.

The Journal of Antimicrobial Chemotherapy
|May 3, 2014
PubMed

Insights

Monitoring drug resistance in children with HIV-1 is essential for effective treatment. This review highlights the need for ongoing studies to guide therapy choices for pediatric HIV drug resistance (HIVDR).

Area of Science:

  • Pediatric Infectious Diseases
  • Virology
  • Public Health

Background:

  • Monitoring drug resistance in pediatric HIV-1 is critical for treatment optimization.
  • Preserving future treatment options for children requires understanding current resistance patterns.

Purpose of the Study:

  • To review existing knowledge on HIV drug resistance (HIVDR) in treatment-naive and pretreated pediatric populations.
  • To analyze HIVDR data across diverse global settings and time periods.

Main Methods:

  • Systematic literature search of PubMed up to May 2013.
  • Inclusion of studies reporting transmitted drug resistance (TDR) and acquired drug resistance mutations (DRM) or pol sequences in pediatric patients.
  • Data extraction included patient demographics, treatment status, geographical location, and resistance testing methodologies.

Main Results:

  • Analysis of 41 studies involving 2538 pediatric HIV-1 patients from 30 countries.
  • HIVDR prevalence varied significantly by country and study period.
  • Non-B HIV-1 variants were common in many pediatric cohorts, with limited data from high-patient-count studies in only five countries.

Conclusions:

  • Systematic and regular studies on pediatric HIV-1 are vital.
  • Findings emphasize the need for tailored first- and second-line antiretroviral therapies for children.
Abstract

Keywords:
HIV-1antiretroviral therapychildrenresistance mutations

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

20.3K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K